Point of Care

Rapid, decentralised testing at the bedside, clinic and field, including immunoassays and portable molecular platforms.

Latest

Point of Care

Phage-Derived Binding Protein Enables Rapid, Culture-Free Detection of A. baumannii

Analytical chemistry March 24, 2026

Significance 6/10 Point of Care

European Physicians Prioritise Rapid Fever Tests for Immunocompromised Patients and Unclear Presentations

BMJ open March 24, 2026

Significance 5/10 Point of Care

Same-Day Hepatitis C Test-and-Treat Model Trialled Using Antibody-Only Screening in Three Countries

BMJ open March 24, 2026

Significance 6/10 Point of Care

Discarded Malaria Rapid Tests Repurposed for Arbovirus Surveillance in Haiti

PLoS neglected tropical diseases March 20, 2026

Significance 6/10 Point of Care

CRISPR-Based Point-of-Care Tests Push Toward Practical H. pylori Screening

ACS sensors March 19, 2026

Significance 5/10 Point of Care

Rapid Diagnostics and Opportunistic Infections Drive Mortality in Advanced HIV Cohort in Brazil

Revista panamericana de salud publica = Pan American journal of public health March 19, 2026

Significance 6/10 Point of Care

Modified Viscoelastic Tests Show Promise for Rapid DOAC Detection at Point of Care

Seminars in thrombosis and hemostasis March 18, 2026

Significance 6/10 Point of Care

Portable Biosensor Combines Two Thalassemia Screening Assays with 90% Concordance to Gold Standard

Current molecular medicine March 18, 2026

Significance 6/10 Point of Care

CRISPR-Cas and Isothermal Amplification Platforms Advance Toward Field-Deployable Pathogen Diagnostics

Talanta March 11, 2026

Significance 5/10 Point of Care

Nipah Virus Diagnostics Advance with Rapid Molecular Tests and Field-Deployable Tools

Cureus February 17, 2026

Significance 4/10

Landmark studies

Point of Care

155 studies

NEJM: CRISPR-Cas9 Gene Editing Achieves 92% Sustained TTR Reduction in Hereditary Amyloidosis The New England journal of medicine 2025 Landmark-class JAMA Meta-Analysis: SGLT2 Inhibitors Reduce Kidney Progression and Death Regardless of Diabetes or Albuminuria JAMA 2026 Landmark-class SGLT2 Inhibitors Protect Kidneys Regardless of Baseline GFR or Albuminuria in 70,000-Patient Meta-Analysis JAMA 2026 Landmark-class CRISPR Gene Editing of ANGPTL3 Achieves Up to 80% Lipid Target Reduction in Phase 1 Cardiovascular Trial The New England journal of medicine 2025 Landmark-class Lancet RCT: CRP Point-of-Care Decision Tool Safely Cuts Pediatric Antibiotic Prescribing by 28% Lancet (London, England) 2025 Landmark-class Acalabrutinib-Obinutuzumab Delivers Durable Survival Benefit in Treatment-Naive CLL at 6-Year Follow-Up Blood 2025 Landmark-class CRISPR-Engineered Allogeneic CAR-T Cells Induce Remission in Refractory Lupus Nature medicine 2025 Landmark-class Lancet ENERGIZE Trial: Mitapivat Raises Haemoglobin in Non-Transfusion-Dependent Thalassaemia Lancet (London, England) 2025 Landmark-class Phase 2 Trial Confirms CRISPR-Based NTLA-2002 Reduces Hereditary Angioedema Attacks by 75-77% vs Placebo The New England journal of medicine 2024 Landmark-class BRILLIANCE Trial: In Vivo CRISPR Gene Editing Improves Vision in Inherited Retinal Degeneration The New England journal of medicine 2024 Landmark-class Lancet Oncology: Largest CMMRD Cohort Reveals 90% Cancer Incidence by Age 18 and Gene-Specific Outcomes The Lancet. Oncology 2024 Landmark-class Single-Dose In Vivo CRISPR Editing of KLKB1 Reduces Angioedema Attacks by Up to 97% in Phase 1 Trial The New England journal of medicine 2024 Landmark-class Five-Year ZUMA-1 Follow-Up: 43% of Refractory Lymphoma Patients Alive After Axi-cel CAR T Therapy Blood 2023 Landmark-class Large Individual Patient Data Analysis Quantifies the Prognostic Cost of p16/HPV Discordance in Oropharyngeal Cancer The Lancet. Oncology 2023 Landmark-class Non-Viral CRISPR-Edited Neoantigen-Specific T Cells Traffic to Tumours in First-in-Human Solid Cancer Trial Nature 2022 Landmark-class POC Nucleic Acid Testing Dramatically Accelerates HIV Treatment in Infants Lancet (London, England) 2022 Landmark-class NEJM Trial: Decentralised On-Site Molecular TB Testing Increases Diagnosis and Same-Day Treatment The New England journal of medicine 2021 Landmark-class Cilta-cel CAR T-Cell Therapy Achieves 97% Response Rate in Heavily Pretreated Multiple Myeloma Lancet (London, England) 2021 Landmark-class First-in-Human Trial of Multiplex CRISPR-Cas9 Edited T Cells Shows Safety and Durable Engraftment in Cancer Science (New York, N.Y.) 2020 Landmark-class NEJM PACE Trial: CRP Point-of-Care Testing Safely Cuts Antibiotic Prescribing in COPD Exacerbations The New England journal of medicine 2019 Landmark-class CRISPR-Cas Systems: From Genome Editing to Programmable Diagnostics Science (New York, N.Y.) 2018 Landmark-class IFCC Framework for Implementing High-Sensitivity Cardiac Troponin Point-of-Care Testing in Acute Care Settings Clinical chemistry and laboratory medicine 2026 Landmark-class Obicetrapib Lowers LDL-C by 36% in Familial Hypercholesterolaemia: BROOKLYN Trial Results Nature medicine 2026 Landmark-class CASTLE Basket Trial: CD19 CAR-T Achieves Remission Across Three Autoimmune Diseases Nature medicine 2026 Landmark-class Permethrin-Treated Baby Wraps Cut Childhood Malaria Incidence by 66% in Ugandan RCT The New England journal of medicine 2025 Landmark-class

Show all 155 studies